The study team evaluated routine electronic records from 18 primary care clinics in three districts, covering adults who initiated or re‑initiated ART from January 2022 through March 2025. Investigators reported that South Africa’s April 2023 guideline revision moved the scheduled first viral load (VL) test from 6 months to 3 months after ART start and accelerated eligibility for differentiated care from 7 to 4 months for clients who were virally suppressed. Data indicated a marked change in testing practice after implementation: 3‑month VL testing rose immediately and, by the end of the observation period, reached reported coverage between 72% and 85% across sites. Before implementation, only 27% of participants had their first documented VL within the 3‑month window; after the policy change, uptake increased substantially, according to the interrupted time series analyses the authors described.
Clinic assignment to longer visit intervals (defined as visit intervals of greater than or equal to 6 months) for clients who were virally suppressed at 3 months increased after the guideline change. The authors noted that across districts, the proportion of virally suppressed clients assigned to ≥6‑month visit intervals rose to between 48% and 71% by study end. This shift signals a rapid operational adaptation in differentiated service delivery practices, but uptake was not uniform: incomplete adoption of both earlier testing and extended intervals persisted at some sites, the investigators reported.
At the first documented VL assessment, suppression prevalence was similar regardless of whether the test occurred at 3 or 6 months. The cohort showed a 72% suppression rate among clients initially tested at 3 months and a 72% suppression rate among those initially tested at 6 months. The authors used modified Poisson regression to compare relative risks for viral suppression between these groups and described no meaningful difference in first‑test suppression between the two scheduled testing windows.
A second routine VL result was available for 62% of clients who had an initial VL recorded in either the 3‑ or 6‑month window. Among those with a documented second VL, 82% were virally suppressed. The data the investigators reported suggest that, when follow‑up testing was captured in records, the majority of clients maintained suppression on a second assessment. The authors cautioned, however, that missing VL results limited the completeness of longitudinal outcome measurement.
The study team examined whether assignment to longer visit intervals after 3‑month suppression was linked to later suppression. Adjusted analyses showed no association between assignment to ≥6‑month visit intervals and subsequent viral suppression; the reported adjusted relative risk was 1.02 with a 95% confidence interval of 0.99–1.06. Authors concluded that longer scheduled intervals were not associated with poorer short‑term virologic outcomes in this cohort, according to their analysis of routine program data.
Substantial missing VL data restricted some comparisons and the authors urged cautious interpretation of findings that rely on complete testing records. At first VL assessment, 19% of participants had VL tests outside the defined 3‑ or 6‑month windows and 25% had no documented VL test at all, per the source. The authors identified incomplete uptake of recommended testing schedules and of assignment to extended visit intervals as implementation gaps that remain to be addressed. They reported that interrupted time series and regression methods were used but the source did not provide additional trial‑level operational details beyond what is summarized here. The paper ends by noting the need for continued evaluation of longer‑term outcomes, and by flagging missing data and variable uptake across sites as principal limitations documented by the study team.